Life Sciences Voice

Life Sciences Voice Life Sciences Voice is the leading resource for life sciences executives to get crucial insights

Life Sciences Voice is the leading resource for life sciences executives to get crucial insights, explore the latest innovations, and learn about industry trends. Life Sciences Voice provides the community with thought-provoking commentary in multiple formats covering a range of issues from drug discovery to commercial success.

Sword Health, a digital healthcare startup, has achieved a value of $4 billion following a $40 million investment round ...
06/21/2025

Sword Health, a digital healthcare startup, has achieved a value of $4 billion following a $40 million investment round headed by General Catalyst, a venture capital firm.
The funding round, which included participation from Lince Capital, Khosla Ventures and Comcast Ventures, will facilitate the company’s expansion and enhancement of its artificial intelligence capabilities.

Ventyx Biosciences has published new Phase 2a data regarding its oral drug candidate VTX3232, which was tested in patien...
06/21/2025

Ventyx Biosciences has published new Phase 2a data regarding its oral drug candidate VTX3232, which was tested in patients with early-stage, idiopathic Parkinson’s disease. The study, conducted over a 28-day period, involved administering a 40-mg daily dose of the compound to ten participants.

Bavarian Nordic has finalized an agreement to sell a Priority Review Voucher (PRV) granted by the U.S. Food and Drug Adm...
06/20/2025

Bavarian Nordic has finalized an agreement to sell a Priority Review Voucher (PRV) granted by the U.S. Food and Drug Administration (FDA) in connection with the approval of its chikungunya vaccine, Vimkunya, for $160 million. The Danish vaccine developer disclosed the sale on Wednesday, noting that the identity of the purchaser has not been made public.

Immuneering has reported a six-month overall survival (OS) rate of 94% in a phase 2a clinical trial evaluating its MEK i...
06/20/2025

Immuneering has reported a six-month overall survival (OS) rate of 94% in a phase 2a clinical trial evaluating its MEK inhibitor, atebimetinib, in patients with first-line pancreatic cancer. Based on these results, the company is preparing to initiate a pivotal trial aimed at securing accelerated approval.

GSK has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited (BBIL), an Ind...
06/18/2025

GSK has licensed its Shigella vaccine candidate, altSonflex1-2-3, to Bharat Biotech International Limited (BBIL), an Indian biotechnology firm. The agreement enables Bharat Biotech to proceed with the next phase of clinical development and potentially deliver the vaccine to low- and middle-income countries, where Shigella is a leading cause of illness and death among children under five.

UroGen Pharma has received FDA approval for its intravesical therapy, Zusduri, marking the first authorized treatment sp...
06/17/2025

UroGen Pharma has received FDA approval for its intravesical therapy, Zusduri, marking the first authorized treatment specifically for adult patients in the U.S. diagnosed with recurrent low-grade intermediate-risk non-muscle invasive bladder cancer (LG-IR-NMIBC).

NextCure has signed a licensing deal valued at up to $745 million for the rights outside Greater China to Simcere Zaimin...
06/17/2025

NextCure has signed a licensing deal valued at up to $745 million for the rights outside Greater China to Simcere Zaiming’s experimental cancer therapy, SIM0505. The agreement is part of NextCure’s ongoing transition toward developing antibody-drug conjugates (ADCs) and includes milestone-based payments as well as royalties on potential future sales.

Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest breakthr...
06/14/2025

Welcome to this week’s edition of the Life Sciences Voice Top Five Newsletter, your go-to source for the latest breakthroughs in the life sciences industry! This time, we’re looking at the FDA’s approval for Merck’s RSV treatment in infants, Sanofi’s acquisition of BluePrint Medical Corporation, why the FDA has halted Rocket Pharmaceuticals’ gene therapy trial, and more! Stay informed and inspired by the innovations driving life sciences forward.

https://www.linkedin.com/pulse/life-sciences-voice-top-five-things-week-lifescivoice-hsgcf

Novo Nordisk has entered into a license agreement with Deep Apple Therapeutics valued at up to $812 million. The collabo...
06/14/2025

Novo Nordisk has entered into a license agreement with Deep Apple Therapeutics valued at up to $812 million. The collaboration centers on the development of small molecules targeting a G-protein-coupled receptor (GPCR) that is unrelated to incretins, for use in treating cardiometabolic diseases, including obesity.

As President of the US unit for Novartis, Victor Bultó is pursuing a bold strategy to reimagine medicine and deliver on ...
06/13/2025

As President of the US unit for Novartis, Victor Bultó is pursuing a bold strategy to reimagine medicine and deliver on the company’s responsibility to unlock the potential for helping patients in the world’s largest healthcare market.

Victor is driven by the pressing need to translate medicines to outcomes – at scale and equitably – and transform the patient experience to help mitigate the challenges people living with disease face in getting diagnosed, obtaining medicine, and staying on treatment within the complex US healthcare system.

We have a duty to do better for patients and customers whose experiences are being shaped by digital technology and new business models in most other aspects of their lives outside of healthcare. This takes a customer-obsessed, data-driven organization committed to meeting patients and providers in, and becoming a part of, the ecosystems in which they live.

Prior to this role, Victor served as President, Novartis Pharmaceuticals Corporation, leading the US pharmaceuticals business. Victor has been with Novartis for 19 years and has broad, multinational experience in the healthcare industry. He has worked across every therapeutic area at Novartis Pharmaceuticals and played critical roles in launching numerous products.

He held various other positions at Novartis, including Head of the US Alcon Pharmaceuticals Franchise and Head of the Neuroscience Franchise for Region Europe, where he had responsibility for the overall strategy, growth and profitability of these businesses. Before joining Novartis, Victor was a medical device sales representative.

Victor has a strong track-record as a people-first leader with a focus on creating a culture where each individual can show up every day as their authentic self to best serve the interests of people living with disease.

I feel strongly that culture is built through the actions of every individual in the organization. It’s important for people at every level to feel included, supported, accountable and empowered to create the culture that will help propel us into the future.

Outside of Novartis, Victor is an avid photographer and enjoys spending time with his wife and three daughters.

For any concerns or edits, please DM on LinkedIn.

Insmed has announced favorable outcomes from its phase 2b clinical trial assessing treprostinil palmitil inhalation powd...
06/13/2025

Insmed has announced favorable outcomes from its phase 2b clinical trial assessing treprostinil palmitil inhalation powder (TPIP) in patients with pulmonary arterial hypertension (PAH). The investigational therapy, developed as a prodrug of United Therapeutics’ treprostinil (Tyvaso), is formulated for once-daily administration using a capsule-based inhalation device.

The U.S. Food and Drug Administration has approved Merck’s monoclonal antibody, clesrovimab, which will be marketed as E...
06/12/2025

The U.S. Food and Drug Administration has approved Merck’s monoclonal antibody, clesrovimab, which will be marketed as Enflonsia, for the prevention of lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants entering or born during their first RSV season. The authorization came one day ahead of the agency’s scheduled decision deadline.

Address

New York, NY

Alerts

Be the first to know and let us send you an email when Life Sciences Voice posts news and promotions. Your email address will not be used for any other purpose, and you can unsubscribe at any time.

Contact The Business

Send a message to Life Sciences Voice:

Share